Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company's technology and growth of its commercial use cases.
The feasibility study was meant to see whether personalized cancer genetic sequencing and drug sensitivity recommendations could be done in a "clinically reasonable amount of time."
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
Suki's pilot program with Sutter will introduce the Redwood City-based company's technology across three specialties: primary care, dermatology and orthopedics.
The company's initial program, known as ND-1000, is a combination of an existing generic cancer medication with a natural product that is meant to boost the effectiveness of CAR T-Cell therapy.
The goal of the business is to help physicians identify the most suitable combinations of FDA-approved treatments that can be immediately prescribed.